EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
"The granting of this patent in support of our CYB005 phenethylamines program reinforces our commitment to expanding the breadth of innovative development work beyond our clinical tryptamine programs," said Doug Drysdale, CEO of Cybin.The United States Patent and Trademark Office (USPTO) has granted U.S. patent 12,122,741, which claims the composition of matter of lead preclinical candidates in Cybin Inc's (NYSE:CYBN) CYB005 phenethylamines program.
美國專利商標局（USPTO）已授予美國專利12,122,741，該專利主張了Cybin Inc（紐交所:CYBN）的CYB005苯乙胺計劃的前臨床候選物質的組成。
The company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for Central Nervous System (CNS) disorders.
該公司正在研究CYB005計劃中新型分子，採用非致幻劑劑量，用於中樞神經系統（CNS）疾病。
In addition, the company is continuing to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline, as well as targeted serotonin 5-HT1A and 5-HT2Creceptor agonists.
此外，公司正在繼續探索其更廣泛的發現管線中的非致幻神經可塑劑，以及有針對性的5-HT1A和5-HT2C受體激動劑。
"The granting of this patent in support of our CYB005 phenethylamines program reinforces our commitment to expanding the breadth of innovative development work beyond our clinical tryptamine programs," said Doug Drysdale, CEO of Cybin.
「在支持我們的CYB005苯乙胺計劃方面授予該專利，強化了我們將創新開發工作的廣度擴展到臨床色胺類藥物以外的承諾，」 Cybin的首席執行官道格·德賽爾（Doug Drysdale）表示。
"Non-hallucinogenic 5-HT receptor agonists have garnered a great deal of attention in recent years, and we are eager to continue exploring their clinical potential in CNS disorders. While our primary focus remains on our clinical-stage psychiatry programs, CYB003 and CYB004, we believe that other programs like CYB005 that target CNS disorders have the potential to address significant unmet medical needs."
「非致幻性的5-Ht受體激動劑近年來受到了極大關注，我們渴望繼續探究它們在CNS疾病中的臨床潛力。儘管我們的主要焦點仍在我們的臨床階段的精神病學計劃CYB003和CYB004上，但我們相信像CYB005這樣針對CNS疾病的其他計劃有望解決重大的未滿足醫療需求。」
In August, Cybin held a Type B Initial Breakthrough Therapy Meeting with the FDA and said it plans to initiate its Phase 3 pivotal trial of CYB003 for the adjunctive treatment of major depressive disorder in late summer of 2024.
八月份，Cybin與FDA舉行了B型初步突破療法會議，並表示計劃在2024年夏末開始CYB003作爲輔助治療重度抑鬱症的第三階段關鍵試驗。
12-month efficacy results from the Phase 2 study of CYB003 in major depressive disorder are expected in the fourth quarter of 2024.
CYB003在重度抑鬱症的2期研究的12個月療效結果預計將於2024年第四季度公佈。
In July, the company received U.S. patent no. 12,042,564, providing additional patent protection for the CYB004 program under development for Generalized Anxiety Disorder (GAD).
七月份，公司獲得了美國專利號12,042,564，爲其開發的針對廣泛性焦慮障礙（GAD）的CYB004計劃提供了額外的專利保護。
Price Action: CYBN stock closed at $10.93 on Wednesday.
價格走勢：CYBN股票週三收盤價爲10.93美元。
- Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm.
- 波士頓科學暫停在藥物未經治療的心律不齊患者中進行Farapulse研究的招募。
譯文內容由第三人軟體翻譯。
